ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
A systematic review and meta-analysis on survival, pathological response, and safety of durvalumab in early-stage non-small cell lung cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDurvalumab is a selective anti-PD-L1 monoclonal antibody and an emerging perioperative treatment for resectable non-small cell lung cancer (NSCLC). However, its survival benefit, Pathological response, and safety require comprehensive evaluation.
methodsA systematic search of PubMed/MEDLINE, Cochrane Library, and Embase (2000-2026) was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Eligible studies evaluated perioperative durvalumab (neoadjuvant, adjuvant, or both) in patients with resectable NSCLC. Primary endpoints included overall survival (OS), event-free survival (EFS), disease-free survival (DFS), major Pathological response (mPR), and Pathological complete response (pCR). Safety outcomes included grade ≥ 3 adverse events (AEs), treatment-emergent AEs (TEAEs), and discontinuation rates. Pooled meta-analysis included overall hazard ratio (HR) and risk ratio (RR) with 95% confidence intervals (CIs) for the specified outcomes. Quality of the included studies was assessed using Cochrane RoB 2.0 and JBI Critical Appraisal Checklist.
resultsFourteen studies were included. Durvalumab treatment showed a significant trend toward improvement of EFS in the perioperative studies (HR 0.69; 95% CI: 0.61-0.78; I
conclusionsDurvalumab-based perioperative treatment strategies are associated with favorable survival trends, a robust increase in pCR, and a strong improvement in perioperative mPR across early-stage NSCLC settings.
Indexed as
Identifiers
42430099What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.